These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 12784063)

  • 21. Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer.
    Khuri FR; Rigas JR; Figlin RA; Gralla RJ; Shin DM; Munden R; Fox N; Huyghe MR; Kean Y; Reich SD; Hong WK
    J Clin Oncol; 2001 May; 19(10):2626-37. PubMed ID: 11352954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of bexarotene, a selective agonist of the retinoid receptor X (RXR), and tazarotene, a selective agonist of the retinoid acid receptor (RAR), on bone metabolism in rats.
    Nowak B; Matuszewska A; Filipiak J; Nikodem A; Merwid-Ląd A; Pieśniewska M; Fereniec-Gołębiewska L; Kwiatkowska J; Szeląg A
    Adv Med Sci; 2016 Mar; 61(1):85-9. PubMed ID: 26569440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
    Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W
    Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the Efficacy and Safety of Bexarotene and Photo(Chemo)Therapy Combination Therapy and Bexarotene Monotherapy for Cutaneous T-Cell Lymphoma.
    Morita A; Tateishi C; Ikumi K; Hayashi D; Nakada A; Nishihara H; Torii K; Nishida E; Tsuruta D
    Dermatol Ther (Heidelb); 2022 Mar; 12(3):615-629. PubMed ID: 35084694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protective effects of a topical antioxidant mixture containing vitamin C, ferulic acid, and phloretin against ultraviolet-induced photodamage in human skin.
    Oresajo C; Stephens T; Hino PD; Law RM; Yatskayer M; Foltis P; Pillai S; Pinnell SR
    J Cosmet Dermatol; 2008 Dec; 7(4):290-7. PubMed ID: 19146606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Central hypothyroidism associated with retinoid X receptor-selective ligands.
    Sherman SI; Gopal J; Haugen BR; Chiu AC; Whaley K; Nowlakha P; Duvic M
    N Engl J Med; 1999 Apr; 340(14):1075-9. PubMed ID: 10194237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma.
    Yen WC; Prudente RY; Lamph WW
    Breast Cancer Res Treat; 2004 Nov; 88(2):141-8. PubMed ID: 15564797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB.
    D'Acunto C; Gurioli C; Neri I
    J Dermatolog Treat; 2010 Jan; 21(1):45-8. PubMed ID: 19603308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
    Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
    Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.
    Breneman D; Duvic M; Kuzel T; Yocum R; Truglia J; Stevens VJ
    Arch Dermatol; 2002 Mar; 138(3):325-32. PubMed ID: 11902983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral bexarotene for post-transplant cutaneous T-cell lymphoma.
    Lewis DJ; Huang S; Duvic M
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28748653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.
    Rigas JR; Dragnev KH
    Oncologist; 2005 Jan; 10(1):22-33. PubMed ID: 15632250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms.
    McGinnis KS; Junkins-Hopkins JM; Crawford G; Shapiro M; Rook AH; Vittorio CC
    J Am Acad Dermatol; 2004 Mar; 50(3):375-9. PubMed ID: 14988678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial.
    Heald P; Mehlmauer M; Martin AG; Crowley CA; Yocum RC; Reich SD;
    J Am Acad Dermatol; 2003 Nov; 49(5):801-15. PubMed ID: 14576658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.
    Hermann TW; Yen WC; Tooker P; Fan B; Roegner K; Negro-Vilar A; Lamph WW; Bissonnette RP
    Lung Cancer; 2005 Oct; 50(1):9-18. PubMed ID: 15993980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
    Scarisbrick JJ; Morris S; Azurdia R; Illidge T; Parry E; Graham-Brown R; Cowan R; Gallop-Evans E; Wachsmuth R; Eagle M; Wierzbicki AS; Soran H; Whittaker S; Wain EM
    Br J Dermatol; 2013 Jan; 168(1):192-200. PubMed ID: 22963233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modeling, synthesis and biological evaluation of potential retinoid X receptor-selective agonists: novel halogenated analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).
    Furmick JK; Kaneko I; Walsh AN; Yang J; Bhogal JS; Gray GM; Baso JC; Browder DO; Prentice JL; Montano LA; Huynh CC; Marcus LM; Tsosie DG; Kwon JS; Quezada A; Reyes NM; Lemming B; Saini P; van der Vaart A; Groy TL; Marshall PA; Jurutka PW; Wagner CE
    ChemMedChem; 2012 Sep; 7(9):1551-66. PubMed ID: 22927238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
    Stern DK; Lebwohl M
    J Drugs Dermatol; 2002 Sep; 1(2):134-6. PubMed ID: 12847736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topical 8-methoxypsoralen enhances the therapeutic results of targeted narrowband ultraviolet B phototherapy for plaque-type psoriasis.
    Asawanonda P; Amornpinyokeit N; Nimnuan C
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):50-5. PubMed ID: 18181973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and in vitro resistance to bexarotene in adult T-cell leukemia: loss of RXR-alpha receptor.
    Lin JH; Kim EJ; Bansal A; Seykora J; Richardson SK; Cha XY; Zafar S; Nasta S; Wysocka M; Benoit B; Rook AH; Fakharzadeh SS
    Blood; 2008 Sep; 112(6):2484-8. PubMed ID: 18559673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.